Targeting conditions including CEP290-associated Leber congenital amaurosis 10 [LCA10], rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP), wet age-related macular degeneration, proliferative diabetic retinopathy, and proliferative vitreoretinopathy, this novel approach has been used [48]. The gene discussed is CEP290; the disease is proliferative vitreoretinopathy.